Related Experiment Videos
New frontiers in therapy of malignant gliomas
1Department of Neuro-oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Abstract:
The prognosis of patients with malignant gliomas remains dismal despite the development of a multidisciplinary approach to their treatment. There is a strong need for novel therapeutic approaches that can make a definite impact in the clinical course of these tumours. Although there have been several advances in diagnostic modalities, surgical techniques and cytotoxic therapies, the development of newer therapies has been hampered by the limited understanding of the factors that determine the biological nature of gliomas. However, inroads are now being made into the understanding of the genetic make-up, biological behaviour and therapeutic response of these tumours, which are expected to pave the way for new modes of treatment. In this article, we review the advances made in the identification of potential targets for glioma therapy and the recent clinical trials utilising biological therapies and newer cytotoxic agents.
Insights
Malignant glioma prognosis is poor, necessitating novel therapies. Recent research into glioma genetics and biology offers new treatment targets and clinical trials for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Malignant gliomas have a poor prognosis despite multidisciplinary treatment.
- Limited understanding of glioma biology hinders novel therapeutic development.
- Advances in diagnostics and surgery have not significantly improved outcomes.
Purpose of the Study:
- To review recent advances in identifying therapeutic targets for malignant gliomas.
- To discuss clinical trials involving novel biological therapies and cytotoxic agents for gliomas.
- To highlight the impact of understanding glioma genetics and behavior on future treatments.
Main Methods:
- Literature review of scientific publications.
- Analysis of recent clinical trial data for glioma therapies.
- Synthesis of information on glioma genetics, biology, and therapeutic responses.
Main Results:
- Progress in understanding glioma genetic makeup and biological behavior.
- Identification of potential molecular targets for glioma therapy.
- Initiation of clinical trials for biological and novel cytotoxic agents.
Conclusions:
- Understanding glioma biology is crucial for developing effective treatments.
- New therapeutic strategies are emerging based on genetic and biological insights.
- Future treatments hold promise for improving malignant glioma prognosis.